C3.ai reports its fiscal Q4 results tonight — and it walks in wearing the most heavily-shorted badge in enterprise software.
Short interest has climbed to 35.6% of the free float, the highest level in the trailing month, after a steady grind higher from roughly 32% at the start of May. The week-on-week gain of just over 2% reinforces the direction of travel: bears have been adding, not retreating, ahead of the print. That is a significant position. With FINRA's official fortnightly data clocking 47.1 million shares sold short and days-to-cover above ten, unwinding this position is not a fast exercise. The ORTEX short score of 75.2 places the stock in the bottom three percentiles of all names on a short-score basis — a concrete measure of how unusual the bearish pressure is relative to peers.
The borrow market, however, tells a more nuanced story. Cost to borrow is low — 0.63% annually — which has barely moved in weeks despite the rising short interest. Availability stands at 168%, meaning roughly 1.7 shares remain available to lend for every share currently borrowed. That is a comfortably supplied lending pool and a world away from a squeeze dynamic. Bears can add positions without scrambling for stock. The 52-week low on availability was 27.7%, so today's reading represents an unusually relaxed borrow environment for a name this heavily shorted. Options positioning is equally calm: the put/call ratio of 0.54 is fractionally below its 20-day average, with a z-score of -0.33 — no unusual hedging, no defensive pile-on into the event.
The Street remains deeply divided. Analysts cluster mostly in neutral-to-negative territory, with JPMorgan carrying an Underweight at $7 and DA Davidson at Underperform with the same target. Wedbush stands apart at Outperform with a $15 target, arguing the federal AI pipeline is genuine — 139% growth in federal bookings year-over-year backs that view. But the mean analyst target of $8.91 is well below the current price of $11.18, making the consensus a de facto sell signal at today's levels. The last round of analyst changes following February's earnings was broadly negative, with most firms slashing targets into the single digits after a revenue miss and a gutted full-year guide. The three May 13 actions — DA Davidson flat, Canaccord nudging to $8, Wedbush reiterating $15 — reflect a street still waiting for proof, not ready to capitulate or upgrade.
Insider activity adds another layer of caution. Founder and Executive Chairman Thomas Siebel sold over $4.4 million in stock across three transactions in May, all priced between $8.65 and $9.27. CEO Stephen Ehikian sold a further $429,000 at the end of March. The aggregate 90-day insider net is a sale of approximately $14.3 million across the leadership group. These are not small, routine disposals — Siebel's May 15 transaction alone accounted for nearly 370,000 shares. Insider selling at prices notably below today's $11.18 suggests those sales were conducted under pre-established plans or at levels management considered fair, which now looks prescient given the stock's subsequent run. BlackRock added 810,000 shares through April, a notable institutional positive, but Millennium Management entered with 1.8 million new shares as a short-biased name's institutional register gets complicated.
The one data point that genuinely complicates the bear case is the recent price action. AI is up 16.6% on the week and 22% over the past month, closing at $11.18 — all while short interest was rising. That is a squeeze-adjacent dynamic where the stock rallied into an earnings event against building short positioning. The February print ended badly: the stock fell 17% the next day and gave back another 8% over the following five sessions after management dramatically cut the full-year revenue guide. Tonight's numbers carry the same binary weight — the gap between Wedbush's bull case and JPMorgan's bear case is not a matter of degree but of fundamental disagreement about whether C3.ai's federal AI pivot is real revenue or runway.
What to watch: whether tonight's revenue trajectory and any revised guidance can credibly close the gap between the $11 stock price and an analyst consensus anchored closer to $9.
See the live data behind this article on ORTEX.
Open AI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
